116476-16-5

Basic information

• Product Name: Levosemotiadil
• Synonyms: Levosemotiadil;[2S,(-)]-3,4-Dihydro-2-[5-methoxy-2-[3-[methyl[2-[(1,3-benzodioxol-5-yl)oxy]ethyl]amino]propoxy]phenyl]-4-methyl-2H-1,4-benzothiazin-3-one
• CAS NO: 116476-16-5
• Molecular Formula: C₂₉H₃₂N₂O₆S
• Molecular Weight: 536.64
• Mol File: 116476-16-5.mol

Chemical Properties

• Boiling Point: 727.3°Cat760mmHg
• Flash Point: 393.7°C
• Appearance: /
• Density: 1.263g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.611
• CAS DataBase Reference: Levosemotiadil(CAS DataBase Reference)
• NIST Chemistry Reference: Levosemotiadil(116476-16-5)
• EPA Substance Registry System: Levosemotiadil(116476-16-5)

Safety Data

• Hazardous Substances Data: 116476-16-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Levosemotiadil is used as an antidepressant medication for the treatment of major depressive disorder. It is employed to alleviate symptoms of depression by modulating the levels of serotonin and norepinephrine in the brain, leading to an improvement in mood.
Common side effects associated with the use of levosemotiadil include nausea, dizziness, dry mouth, constipation, and an increased heart rate. It is crucial for patients to be aware of these potential side effects and to discuss them with their healthcare provider to determine the best course of treatment.

InChI:InChI=1/C29H32N2O6S/c1-30(14-16-34-21-10-12-25-26(18-21)37-19-36-25)13-6-15-35-24-11-9-20(33-3)17-22(24)28-29(32)31(2)23-7-4-5-8-27(23)38-28/h4-5,7-12,17-18,28H,6,13-16,19H2,1-3H3/t28-/m0/s1

Upstream product

• 123388-07-8 3,4-dihydro-2-<5-methoxy-2<3-ethyl>amino>propoxy>phenyl>-4-methyl-3-oxo-2H-1,4-benzothiazine 
• 93848-31-8 2-<2-(3-chloropropoxy)-5-methoxyphenyl>-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazine 
• 93848-37-4 3,4-Dihydro-2-(2-hydroxy-5-methoxyphenyl)-4-methyl-3-oxo-2H-1,4-benzothiazine 
• 116354-42-8 N-methyl-N-<2-<3,4-(methylenedioxy)phenoxy>ethyl>amine 

Related news

Regular ArticleBinding Study of Semotiadil and Levosemotiadil (cas 116476-16-5) with α1-Acid Glycoprotein Using High-Performance Frontal Analysis08/13/2019

High-performance frontal analysis (HPFA) was used to investigate the binding properties of human α1-acid glycoprotein (AGP) with semotiadil ((R)-isomer, Ca-channel blocker) and its antipode levosemotiadil ((S)-isomer, Ca- and Na-channel blockers). An on-line HPLC system consisting of a HPFA col...detailed

Relevant articles and documents

Synthesis and Ca2+ Antagonistic Activity of 2--5-methoxyphenyl>-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazines

As an extension of the previous investigation (J.Med.Chem. 1988, 31, 919), we synthesized a series of 2-5-methoxyphenyl>-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazines (3) and evaluated their Ca2+ antagonistic activities.Ca2+ antagonistic activity was measured with isolated depolarized guinea pig taenia cecum.On the basis of their potent Ca2+ antagonistic activity, six benzothiazines were selected and further evaluated for their vasocardioselectivity.Among these six compounds, the key compound 15 ethyl>amino>propoxy>phenyl>- 4-methyl-3-oxo-2H-1,4-benzothiazine hydrogen fumarate was recognized as having the lowest cardioselectivity.Following optical resolution, the absolute configuration of the compound's optically active enantiomer was determined by means X-ray crystallography of a synthetic precursor (+)-4a.The Ca2+ antagonistic activity of 15 was found to reside primarily in (+)-15 (which was about 7 times more potent than (-)-15).The in vitro study showed that (+)-15 had a low cardioselectivity compared to verapamil and diltiazem.This result suggests that (+)-15 would exhibit less adverse effects due to cardiac inhibition than diltiazem and verapamil in therapeutic use.